Treovir, Inc.
Birmingham, AL · Founded 2019 · CIK 0001825493 · Biotech · Private
G207, an oncolytic herpes simplex virus immunotherapy for brain tumors
treovir.com →- Grants
- $4.6M
- 5 awards
- Sector median: 1
- Raised
- $133K
- 1 Form D · Sep 2020
- 72 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas | $497,320 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas | $2,613,534 | |
| Private capital raised | Form D · SEC | $132,584 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas | $611,912 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas | $1,625 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase II Clinical Trial of G207 HSV To Treat Children with High Grade Gliomas | $890,765 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1482 | PROTHERA BIOLOGICS, INC. | — | $250K |
| 1483 | Modulate Bio Inc. | — | $200K |
| 1484 | Aperta Biosciences, LLC | — | $175K |
| 1485 | Treovir, Inc. | — | $133K |
| 1486 | APTINYX, INC. | — | $95M |
| 1487 | Selva Nexus, Inc. | — | $50K |
| 1488 | NOVOBIOTIC PHARMACEUTICALS, LLC | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Michael ChristiniDirector · Executive Officer
- G. GillespieDirector · Executive Officer
- James MarkertDirector
- Richard WhitelyDirector
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.